BR112021001304A2 - Preparação de emplastro, e, método para fabricar a preparação de emplastro - Google Patents

Preparação de emplastro, e, método para fabricar a preparação de emplastro

Info

Publication number
BR112021001304A2
BR112021001304A2 BR112021001304A BR112021001304A BR112021001304A2 BR 112021001304 A2 BR112021001304 A2 BR 112021001304A2 BR 112021001304 A BR112021001304 A BR 112021001304A BR 112021001304 A BR112021001304 A BR 112021001304A BR 112021001304 A2 BR112021001304 A2 BR 112021001304A2
Authority
BR
Brazil
Prior art keywords
lidocaine
patch
plaster preparation
salt
preparation
Prior art date
Application number
BR112021001304A
Other languages
English (en)
Inventor
Hidetoshi Hamamoto
Masaki Ishibashi
Original Assignee
Medrx Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medrx Co Ltd filed Critical Medrx Co Ltd
Publication of BR112021001304A2 publication Critical patent/BR112021001304A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

preparação de emplastro, e, método para fabricar a preparação de emplastro. este emplastro é bioequivalente às formulações existentes mesmo com maiores concentrações de lidocaína, é altamente seguro, e contém lidocaína ou um sal da mesma, ácido lático, e hidroxiácido com 4 a 6 carbonos; a taxa de penetração na pele da lidocaína quando se aplica o emplastro na pele é em uma faixa apropriada, e o efeito terapêutico da lidocaína é exibido persistentemente por um longo período de tempo. o teor de ácido lático é 0,6 a 1,2 mol por 1 mol de lidocaína ou um sal da mesma.
BR112021001304A 2019-04-24 2020-04-20 Preparação de emplastro, e, método para fabricar a preparação de emplastro BR112021001304A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019082678 2019-04-24
JP2019122757 2019-07-01
PCT/JP2020/017075 WO2020218249A1 (ja) 2019-04-24 2020-04-20 リドカイン含有貼付剤

Publications (1)

Publication Number Publication Date
BR112021001304A2 true BR112021001304A2 (pt) 2021-11-16

Family

ID=72942747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021001304A BR112021001304A2 (pt) 2019-04-24 2020-04-20 Preparação de emplastro, e, método para fabricar a preparação de emplastro

Country Status (10)

Country Link
US (1) US20210369636A1 (pt)
EP (1) EP3960238A4 (pt)
JP (1) JP7496621B2 (pt)
KR (1) KR20220004088A (pt)
CN (1) CN112512634A (pt)
AU (1) AU2020262630A1 (pt)
BR (1) BR112021001304A2 (pt)
CA (1) CA3136186A1 (pt)
MX (1) MX2021012933A (pt)
WO (1) WO2020218249A1 (pt)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
JPH09110680A (ja) * 1995-10-19 1997-04-28 Yuutoku Yakuhin Kogyo Kk 皮膚炎治療貼付剤
CA2378385C (en) * 1999-07-27 2009-01-27 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use including an acid addition salt of a basic drug
US20040142024A1 (en) 1999-07-27 2004-07-22 Hisamitsu Pharmaceutical Co., Inc. Patch formulation for external use
JP2001302501A (ja) 2000-04-17 2001-10-31 Oishi Koseido:Kk 肩こり・膝関節痛・五十肩等の治療用貼付剤
JP4252203B2 (ja) 2000-09-01 2009-04-08 日東電工株式会社 口腔内麻酔製剤
CN101861148B (zh) * 2007-11-11 2013-04-03 美德阿利克斯株式会社 利多卡因胶带制剂
EP2476414B1 (en) 2009-09-07 2015-03-04 NIPRO Patch Co., Ltd. Transdermally absorbable preparation
JPWO2011118604A1 (ja) 2010-03-23 2013-07-04 ニプロパッチ株式会社 含水貼付剤
AU2011277558B2 (en) 2010-07-12 2015-01-22 Teikoku Seiyaku Co., Ltd. Backing Having Three-Layer Structure and Aqueous Patch Using The Backing
US20130224262A1 (en) * 2010-09-03 2013-08-29 Medrx Co., Ltd. Transdermal preparation
WO2012176668A1 (ja) * 2011-06-20 2012-12-27 久光製薬株式会社 リドカイン含有パップ剤
MX2014002115A (es) 2011-08-25 2014-09-25 Nipro Patch Co Ltd Parche de piel adhesivo hidratado.
ES2683006T3 (es) * 2011-09-27 2018-09-24 Itochu Chemical Frontier Corporation Parche no acuoso
US9980920B2 (en) * 2013-09-11 2018-05-29 Medrx Co., Ltd. Base composition for tape agent
TWI629067B (zh) * 2013-10-07 2018-07-11 美商帝國製藥美國股份有限公司 用於經皮輸送非鎮靜量右美托咪啶之方法及組成物
JP6469587B2 (ja) * 2013-12-18 2019-02-13 丸石製薬株式会社 含水型貼付剤
JP2016003196A (ja) * 2014-06-16 2016-01-12 株式会社カネカ 経皮吸収製剤
TW201813635A (zh) 2016-09-16 2018-04-16 日商日絆股份有限公司 貼附劑
EP3639819B1 (en) 2017-06-16 2021-11-10 Medrx Co., Ltd. Anti-inflammatory and analgesic drug for external use

Also Published As

Publication number Publication date
JPWO2020218249A1 (pt) 2020-10-29
MX2021012933A (es) 2021-12-15
KR20220004088A (ko) 2022-01-11
EP3960238A4 (en) 2023-01-25
EP3960238A1 (en) 2022-03-02
AU2020262630A1 (en) 2021-12-16
US20210369636A1 (en) 2021-12-02
WO2020218249A1 (ja) 2020-10-29
JP7496621B2 (ja) 2024-06-07
CN112512634A (zh) 2021-03-16
CA3136186A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
ECSP21003643A (es) Compuestos antagonistas de pcsk9
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
CY1118821T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
MX2019012435A (es) Formulacion farmaceutica.
BRPI0817804A8 (pt) Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
ATE522208T1 (de) Verwendung von phenylbuttersäure oder deren salze zur behandlung von juckreiz
BR112021024933A2 (pt) Formulação e composição de liberação de fármaco tópica, método para liberar pelo menos um fármaco, uso de pelo menos um fármaco e uma formulação de liberação de fármaco, método para fabricar uma composição de liberação de fármaco tópica, e, métodos para prover e administrar alívio de dor
BR112015018549A8 (pt) métodos de tratamento de deficiência de ferro
BR112015006282A2 (pt) composições e métodos de uso de um composto para controle de inapetência
BR112021001304A2 (pt) Preparação de emplastro, e, método para fabricar a preparação de emplastro
FI3302704T3 (fi) Beta-hydroksi-beeta-metylibutyraatin (hmb) koostumuksia ja käyttömenetelmiä rasvamassan vähentämiseksi
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
MX2020012336A (es) Formulacion farmaceutica.
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112015023772A2 (pt) composições de verniz odontolólica estavel e método de fabricação e uso
GB2529597A (en) An oxychlorine oral rinse composition
BR112013020775A2 (pt) processos para controlar dor em cães usando uma solução transdérmica de fentanila
AR120931A1 (es) Fungicidas para prevenir y controlar patógenos fúngicos